1.Atrial Fibrillation as a Risk Factor for Major Adverse Cardiac and Cerebrovascular Events after Non-cardiac Surgery
Korean Circulation Journal 2020;50(2):160-162
No abstract available.
Atrial Fibrillation
;
Risk Factors
5.Reliability and Validity of Angle of Trunk Rotation Measurement Using Smartphone and 3D Printing Technology in Scoliosis
Geum-Dong SHIN ; Seong-gil KIM ; Kyoung KIM
Journal of Korean Physical Therapy 2022;34(6):283-291
Purpose:
The purpose of this study was to compare and analyze the method of measuring the angle of the trunk rotation using a smartphone with 3D smartphone holder compared to a scoliometer, which is a measuring tool used as a method for diagnosing scoliosis in scoliosis patients.
Methods:
Angle of trunk rotation was measured in 21 subjects diagnosed with scoliosis. scoliometer measurement method, a smartphone measurement method with a 3D smartphone holder, a smartphone blind measurement method with a 3D smartphone holder, a smartphone measurement method without a smartphone holder, a smartphone blind measurement method without a smartphone holder, and a total of five measurement methods were repeated three times for comparison and analysis.
Results:
The smartphone measurement method with a 3D smartphone holder has excellent intra-rater reliability of angle of trunk rotation (Rater A; ICC3, 2 ≥ 0.993, Rater B; ICC3, 2 ≥ 0.992). The smartphone blind measurement method with a 3D smartphone holder has excellent inter-rater reliability of angle of trunk rotation (ICC2, 2 ≥ 0.968). The scoliometer measurement method had the highest validity (r = 0.976) with the smartphone measurement method with a 3D smartphone holder, and the blind measurement method without a smartphone holder had the lowest validity (r = 0.886).
Conclusion
These findings, the angle of trunk rotation measured by the smartphone measurement method with a 3D smartphone holder in scoliosis patients showed high reliability and validity compared to the scoliometer measurement method.
6.Impact of Coronary Artery Anatomy on Clinical Course and Prognosis in Apical Hypertrophic Cardiomyopathy: Analysis of Coronary Angiography and Computed Tomography.
Dong Geum SHIN ; Jung Woo SON ; Ji Young PARK ; Jae Woong CHOI ; Sung Kee RYU
Korean Circulation Journal 2015;45(1):38-43
BACKGROUND AND OBJECTIVES: Apical hypertrophic cardiomyopathy (AHCM) is an uncommon variant of hypertrophic cardiomyopathy with a relatively benign course. However, the prognostic factors of AHCM-particularly those associated with coronary artery disease (CAD) and its anatomical subtypes-are not well known. SUBJECTS AND METHODS: We enrolled 98 consecutive patients with AHCM who underwent coronary angiography or coronary computed tomography scanning at two general hospitals in Korea from January 2002 to March 2012. Patient charts were reviewed for information regarding cardiovascular (CV) risk factors, symptoms, and occurrence of CV events and/or mortality. We also reviewed echocardiographic data and angiography records. RESULTS: The mean age at the time of enrollment was 61.45+/-9.78 years, with female patients comprising 38.6%. The proportions of mixed and pure types of AHCM were 34.4% and 65.6%, respectively. CAD was found in 31 (31.6%) patients. The mean follow-up period was 53.1+/-60.7 months. CV events occurred in 22.4% of patients, and the mortality rate was 5.1%. The mixed-type was more frequent in CV event group although this difference was not statistically significant (50% vs. 30%, p=0.097). The presence of CAD emerged as an independent risk factor for CV events in univariate and multivariate Cox regression analysis after adjusting for other CV risk factors. CONCLUSION: Coronary artery disease is an independent risk factor for CV events in AHCM patients. However, AHCM without CAD has a benign natural course, comparable with the general population.
Angiography
;
Cardiomyopathy, Hypertrophic*
;
Coronary Angiography*
;
Coronary Artery Disease
;
Coronary Vessels*
;
Echocardiography
;
Female
;
Follow-Up Studies
;
Hospitals, General
;
Humans
;
Korea
;
Mortality
;
Multidetector Computed Tomography
;
Prognosis*
;
Risk Factors
8.Clinical Outcomes of Intracardiac Echocardiography-Guided Contrast Agent-Free Cryoballoon Ablation in Atrial Fibrillation Patients With Renal Insufficiency
Dong Geum SHIN ; Jinhee AHN ; Sang Hyun PARK ; Sang-Jin HAN ; Hong Euy LIM
Korean Circulation Journal 2024;54(3):113-123
Background and Objectives:
Previous studies have reported an association between impaired renal function and poor outcomes after radiofrequency catheter ablation in patients with atrial fibrillation (AF). However, outcomes of cryoballoon ablation (CBA) in patients with renal insufficiency are not fully elucidated. This study aimed to compare outcomes of CBA in AF patients with chronic kidney disease (CKD) versus those without CKD and to assess changes in renal function over 12 months following CBA.
Methods:
A total of 839 patients (65.1% with non-paroxysmal AF [PAF]) who underwent de novo CBA were prospectively enrolled. We divided patients into two groups based on creatinine clearance rate (CCr) and performed intracardiac echocardiography (ICE)-guided contrast agent-free CBA.
Results:
In comparison with patients without CKD (CCr >50, n=722), those with CKD (CCr ≤50, n=117) were older and predominantly female, had a lower body mass index, and showed a higher prevalence of heart failure and hypertension. Mean CHA 2 DS 2 -VAS score was significantly higher in CKD group than in non-CKD group. Procedure-related complications were not significantly different between two groups. During a mean follow-up period of 25.4±11.9 months, clinical recurrence occurred in 182 patients (21.7%) and not significantly different between two groups. In multivariate analysis, non-PAF and left atrial size were independent predictors of AF recurrence. CCr levels significantly improved over 12 months after CBA in CKD group.
Conclusions
ICE-guided contrast-agent-free CBA showed comparable long-term clinical outcomes without increasing procedure-related complications and improvement of renal function over 12 months following CBA in AF patients with CKD.
9.Clinical Outcomes of Intracardiac Echocardiography-Guided Contrast Agent-Free Cryoballoon Ablation in Atrial Fibrillation Patients With Renal Insufficiency
Dong Geum SHIN ; Jinhee AHN ; Sang Hyun PARK ; Sang-Jin HAN ; Hong Euy LIM
Korean Circulation Journal 2024;54(3):113-123
Background and Objectives:
Previous studies have reported an association between impaired renal function and poor outcomes after radiofrequency catheter ablation in patients with atrial fibrillation (AF). However, outcomes of cryoballoon ablation (CBA) in patients with renal insufficiency are not fully elucidated. This study aimed to compare outcomes of CBA in AF patients with chronic kidney disease (CKD) versus those without CKD and to assess changes in renal function over 12 months following CBA.
Methods:
A total of 839 patients (65.1% with non-paroxysmal AF [PAF]) who underwent de novo CBA were prospectively enrolled. We divided patients into two groups based on creatinine clearance rate (CCr) and performed intracardiac echocardiography (ICE)-guided contrast agent-free CBA.
Results:
In comparison with patients without CKD (CCr >50, n=722), those with CKD (CCr ≤50, n=117) were older and predominantly female, had a lower body mass index, and showed a higher prevalence of heart failure and hypertension. Mean CHA 2 DS 2 -VAS score was significantly higher in CKD group than in non-CKD group. Procedure-related complications were not significantly different between two groups. During a mean follow-up period of 25.4±11.9 months, clinical recurrence occurred in 182 patients (21.7%) and not significantly different between two groups. In multivariate analysis, non-PAF and left atrial size were independent predictors of AF recurrence. CCr levels significantly improved over 12 months after CBA in CKD group.
Conclusions
ICE-guided contrast-agent-free CBA showed comparable long-term clinical outcomes without increasing procedure-related complications and improvement of renal function over 12 months following CBA in AF patients with CKD.
10.Clinical Outcomes of Intracardiac Echocardiography-Guided Contrast Agent-Free Cryoballoon Ablation in Atrial Fibrillation Patients With Renal Insufficiency
Dong Geum SHIN ; Jinhee AHN ; Sang Hyun PARK ; Sang-Jin HAN ; Hong Euy LIM
Korean Circulation Journal 2024;54(3):113-123
Background and Objectives:
Previous studies have reported an association between impaired renal function and poor outcomes after radiofrequency catheter ablation in patients with atrial fibrillation (AF). However, outcomes of cryoballoon ablation (CBA) in patients with renal insufficiency are not fully elucidated. This study aimed to compare outcomes of CBA in AF patients with chronic kidney disease (CKD) versus those without CKD and to assess changes in renal function over 12 months following CBA.
Methods:
A total of 839 patients (65.1% with non-paroxysmal AF [PAF]) who underwent de novo CBA were prospectively enrolled. We divided patients into two groups based on creatinine clearance rate (CCr) and performed intracardiac echocardiography (ICE)-guided contrast agent-free CBA.
Results:
In comparison with patients without CKD (CCr >50, n=722), those with CKD (CCr ≤50, n=117) were older and predominantly female, had a lower body mass index, and showed a higher prevalence of heart failure and hypertension. Mean CHA 2 DS 2 -VAS score was significantly higher in CKD group than in non-CKD group. Procedure-related complications were not significantly different between two groups. During a mean follow-up period of 25.4±11.9 months, clinical recurrence occurred in 182 patients (21.7%) and not significantly different between two groups. In multivariate analysis, non-PAF and left atrial size were independent predictors of AF recurrence. CCr levels significantly improved over 12 months after CBA in CKD group.
Conclusions
ICE-guided contrast-agent-free CBA showed comparable long-term clinical outcomes without increasing procedure-related complications and improvement of renal function over 12 months following CBA in AF patients with CKD.